MNMD vs. BTMD, ACB, USNA, CDXC, CGC, MDWD, CRON, ITOS, STOK, and EXAI
Should you be buying Mind Medicine (MindMed) stock or one of its competitors? The main competitors of Mind Medicine (MindMed) include biote (BTMD), Aurora Cannabis (ACB), USANA Health Sciences (USNA), ChromaDex (CDXC), Canopy Growth (CGC), MediWound (MDWD), Cronos Group (CRON), iTeos Therapeutics (ITOS), Stoke Therapeutics (STOK), and Exscientia (EXAI). These companies are all part of the "medical" sector.
biote (NASDAQ:BTMD) and Mind Medicine (MindMed) (NASDAQ:MNMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, earnings, analyst recommendations, valuation, dividends, risk, profitability, media sentiment and community ranking.
Mind Medicine (MindMed) received 23 more outperform votes than biote when rated by MarketBeat users. However, 100.00% of users gave biote an outperform vote while only 90.00% of users gave Mind Medicine (MindMed) an outperform vote.
biote has a beta of 0.87, meaning that its share price is 13% less volatile than the S&P 500. Comparatively, Mind Medicine (MindMed) has a beta of 2.72, meaning that its share price is 172% more volatile than the S&P 500.
21.7% of biote shares are owned by institutional investors. Comparatively, 27.9% of Mind Medicine (MindMed) shares are owned by institutional investors. 13.9% of biote shares are owned by insiders. Comparatively, 2.1% of Mind Medicine (MindMed) shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
biote has higher revenue and earnings than Mind Medicine (MindMed). Mind Medicine (MindMed) is trading at a lower price-to-earnings ratio than biote, indicating that it is currently the more affordable of the two stocks.
biote currently has a consensus price target of $8.11, suggesting a potential upside of 38.87%. Mind Medicine (MindMed) has a consensus price target of $17.67, suggesting a potential upside of 104.24%. Given biote's higher possible upside, analysts clearly believe Mind Medicine (MindMed) is more favorable than biote.
biote has a net margin of 4.30% compared to biote's net margin of 0.00%. Mind Medicine (MindMed)'s return on equity of -36.67% beat biote's return on equity.
In the previous week, Mind Medicine (MindMed) had 7 more articles in the media than biote. MarketBeat recorded 19 mentions for Mind Medicine (MindMed) and 12 mentions for biote. Mind Medicine (MindMed)'s average media sentiment score of 0.68 beat biote's score of 0.45 indicating that biote is being referred to more favorably in the media.
Summary
biote beats Mind Medicine (MindMed) on 10 of the 16 factors compared between the two stocks.
Get Mind Medicine (MindMed) News Delivered to You Automatically
Sign up to receive the latest news and ratings for MNMD and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding MNMD and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Mind Medicine (MindMed) Competitors List
Related Companies and Tools
